Upgrade to SI Premium - Free Trial

Raymond James Resumes Audentes Therapeutics (BOLD) at Outperform

July 29, 2019 6:58 AM
Raymond James analyst Steven Seedhouse resumes coverage on Audentes Therapeutics (NASDAQ: BOLD) with an Outperform rating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments New Coverage